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Nitric Oxide and Cyclic GMP Signaling in Cancer Therapy
Abstract
The nitric oxide-3’,5’-cyclic guanosine monophosphate signaling pathway (NO-cGMP signaling pathway)
is a well-known signal transduction pathway which elicits several physiological processes including: cell
proliferation, vasodilation, cardiac protection, etc. In this pathway, NO binds to the ferrous heme of
histidine-105 on the prosthetic heme of the β1 subunit of soluble guanylyl cyclase, resulting in the
production of cGMP. This pathway, however, is inhibited in certain cancer cells—as observed in glioma cell
lines. As a result, the production of cGMP is reduced. This mechanism may facilitate uncontrolled tumor
cell growth.
The cancers under research—lung carcinoma, glioma, and pancreatic carcinoma—are all highly malignant
cancers with low survival rates and few effective treatments. To save the lives of 213,920+ U.S. patients
expected to die from these diseases, new therapies must be developed.
We hypothesize that regulating the expression of sGC via pharmacology and/or genetic manipulation in
the aforementioned cancers—which possess lower expression levels of subunits sGCα1 and sGCβ1—will
increase cGMP synthesis.
As experimental approach, the H460 human large lung cell carcinoma cell line, the PA-TU-8988 human
pancreatic adenocarcinoma cell line, and the U87 human glioma cell line were cultured in 2D and 3D
culture. MTT assay, qRT-PCR, Western Blot, and ImageJ analysis were utilized to assess cell proliferation,
detection and quantification of genes and proteins expression, and size of colonies in 3D culture,
respectively.
Research is still continuing; results are not final. The expected results after treatment are: reduced cancer
cell viability, enhanced sGC expression, presence of cGMP, and inhibited tumor growth
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ABSTRACT
The nitric oxide-3’,5’-cyclic guanosine monophosphate signaling pathway (NO-cGMP
signaling pathway) is a well-known signal transduction pathway which elicits several
physiological processes including: cell proliferation, vasodilation, cardiac protection, etc. In this
pathway, NO binds to the ferrous heme of histidine-105 on the prosthetic heme of the β1 subunit
of soluble guanylyl cyclase, resulting in the production of cGMP. This pathway, however, is
inhibited in certain cancer cells—as observed in glioma cell lines. As a result, the production of
cGMP is reduced. This mechanism may facilitate uncontrolled tumor cell growth.
The cancers under research—lung carcinoma, glioma, and pancreatic carcinoma—are all
highly malignant cancers with low survival rates and few effective treatments. To save the lives
of 213,920+ U.S. patients expected to die from these diseases, new therapies must be developed.
We hypothesize that regulating the expression of sGC via pharmacology and/or genetic
manipulation in the aforementioned cancers—which possess lower expression levels of subunits
sGCα1 and sGCβ1—will increase cGMP synthesis.
As experimental approach, the H460 human large lung cell carcinoma cell line, the PATU-8988 human pancreatic adenocarcinoma cell line, and the U87 human glioma cell line were
cultured in 2D and 3D culture. MTT assay, qRT-PCR, Western Blot, and ImageJ analysis were
utilized to assess cell proliferation, detection and quantification of genes and proteins expression,
and size of colonies in 3D culture, respectively.
Research is still continuing; results are not final. The expected results after treatment are:
reduced cancer cell viability, enhanced sGC expression, presence of cGMP, and inhibited tumor
growth
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